![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 51, 49417-49421, December 20, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
,
,
¶**
From the
Unité de Virologie et Immunologie
Cellulaire, Institut Pasteur, 75724 Paris, France, the
¶ Department of Pathology and Kaplan Comprehensive Cancer Center,
New York University School of Medicine, New York, New York 10016, and the
National Institute of Infectious Diseases, Tokyo
208-0011, Japan
Received for publication, July 25, 2002, and in revised form, September 11, 2002
| |
ABSTRACT |
|---|
|
|
|---|
Interferon regulatory factor 7 (IRF7) is an
interferon-inducible transcription factor required for induction
of delayed early interferon Interferon regulatory factors
(IRF)1 are a growing family
of transcription factors that have been implicated in antiviral
defense, cell growth, and immune regulation (for review, see Ref. 1). Ten members of the family have been identified so far: IRF1, IRF2, IRF3, IRF4/Pip/ISCAT, IRF5, IRF6, IRF7, IRF8/ICSBP, IRF9/p48, and the
recently cloned avian IRF10. In addition there are at least four more
distantly related viral homologues encoded by human herpes virus 8 (HHV8) (2, 3). This family is mainly defined by a highly conserved
amino-terminal DNA-binding domain (DBD) characterized by a repeat
containing five tryptophan residues that shows similarities with the
c-myb proto-oncogene DBD (4). Two closely related members of this
family, IRF3 and IRF7, have been identified as direct transducers of
virus-mediated signaling and were shown to play an essential role in
the induction of type I interferon (IFN) (5-8). Previous
studies (5-12) have clearly established that IRF3 and IRF7
activity is regulated by virally induced phosphorylation of serine
residues located in their C terminus. Phosphorylation induces
allosteric changes that result in dimerization and facilitate nuclear
retention, derepress transactivation, and allow specific DNA binding
(9, 10).
Despite the important similarities among IRF family proteins, each
provides a unique biological function. For instance, although both IRF3
and IRF7 are involved in IFN gene expression during viral infections,
IRF3 targets specifically IFN Posttranslational modifications in addition to phosphorylation have
been found to modulate transcription factor activity, including effects
on DNA binding affinity. Histone acetyltransferases (HAT) are
increasingly being recognized as modifiers of non-histone proteins, and
there is a growing body of evidence supporting the notion that
acetylation, like phosphorylation, is an important regulatory protein
modification (for review, see Ref. 14). There are now several reported
families of acetylases exemplified by PCAF/GCN5, p300/CBP, TAF250,
SRC1, and MOZ (for review, see Ref. 15). Of these proteins, two
families, PCAF/GCN5 and p300/CBP, are the most characterized and potent
acetylases compared with other families. HATs function enzymatically by
transferring an acetyl group from acetyl-coenzyme A (acetylCoA) to the
Because of the potential of lysine acetylation to modulate DNA binding,
we investigated the possible acetylation of IRF7. Here we show that
IRF7 is subject to acetylation by the HAT of the PCAF/GCN5 family
in vivo. We mapped the acetylation site to a unique lysine
residue in the DBD at position 92. Using different point mutants, we
provide evidence that this residue is within a region that
distinguishes IRF3 and IRF7 DNA binding affinity and is essential for
DNA binding. Finally we show that acetylation leads to impaired DNA
binding of IRF7 to its cognate DNA.
Cell Culture, Transfections, and Viral Infections--
Human
embryonic kidney 293T cells and monkey kidney COS cells were
maintained in Dulbecco's modified Eagle's medium supplemented with
10% fetal bovine serum. DNA transfections of 293T and COS cells were
performed by standard methods using calcium phosphate. Newcastle
disease virus (NDV), Manhattan strain, was grown in 10-day embryonated
chicken eggs, and viral infections were performed as previously
described (5). Rabbit and mouse antibodies to FLAG were obtained
from Zymed Laboratories Inc. and Sigma, respectively. Rabbit polyclonal antibodies to acetylated lysines were obtained from
Cell Signaling, and rabbit antibodies to IRF7 were from
Zymed Laboratories Inc..
Electromobility Shift Assays (EMSAs) and Affinity DNA Binding
Assays--
EMSAs were performed by incubating nuclear extracts of
each sample (2 µg), prepared as previously described (20), with a labeled double stranded oligonucleotide containing an IFN-stimulated response element (ISRE) sequence derived from the ISG15 gene (21). The
DNA binding affinity assay was performed as follows. Purified GST-IRF7DBD was mixed with 100 ng of purified recombinant PCAF in the
presence of 100 µM acetylCoA for 30 min at 30 °C.
Different amounts of the reaction mixture were then incubated with
biotinylated DNA derived from the ISG15 gene. Bound materials were
purified with streptavidin beads and revealed by immunoblotting using
anti-IRF7 antibodies.
Dissociation Rate Determination--
Dissociation rates of
protein-DNA complexes were determined essentially as described (22)
using nuclear extracts from cells over-expressing IRF7WT or
IRF7GTTR. The approximate half-life of the complex was
determined by quantitative phosphorimaging
Plasmids and Constructs--
Expression constructs for PCAF and
GCN5 were kindly provided by Y. Nakatani and R. Schiltz (National
Institutes of Health, Bethesda, MD) and S. Roth (M. D. Anderson Cancer
Center). The PCAF HAT mutant was provided by M. Rosenfeld. The GCN5 HAT
mutant was described previously (23). Histone deacetylase 1 expression construct was obtained from E. Verdin (Gladstone Institute,
San Francisco, CA). IRF7 KR (K92R) and GTTR (G91T/T93R) mutants
were generated by site directed mutagenesis (Stratagene) and confirmed by DNA sequencing. Mutants of IRF7 Reporter Assays--
Luciferase activities were measured in cell
lysates using commercial reagents as recommended by the manufacturer
(Promega) and were normalized to IRF7 Is Acetylated in Vivo by PCAF and GCN5--
It has now been
clearly demonstrated that virus-induced phosphorylation of IRF7
is an essential event for its activation (10, 13). We investigated
other potential posttranslational modifications that may influence IRF7
activity. Recently, two other IRF family members, IRF1 and IRF2, have
been shown to be acetylated by p300 and to a lesser degree by PCAF
(24). To test whether IRF7 was acetylated in vivo,
FLAG-tagged IRF7 was transfected and IRF7 was detected using an
anti-acetylated lysine antibody after the extracts had been subjected
to immunoprecipitation with anti-FLAG antibodies. As previously
observed, a slower migrating form of IRF7 corresponding to
phosphorylated IRF7 was detected in NDV-infected extracts in addition
to the latent IRF7 found in control extracts (5). Acetylated
IRF7 could be observed in both NDV-infected and uninfected extracts,
indicating that IRF7 is basally acetylated in the cell (Fig.
1A). To identify the enzyme
responsible for IRF7 acetylation, a set of acetyltransferases (p300,
GCN5, and PCAF) as well as the corresponding enzymatically inactive
mutants (HAT mutants), were co-transfected with FLAG-tagged IRF7 in
293T cells. IRF7 was immunoprecipitated with anti-FLAG antibodies and subjected to an anti-acetylated lysine Western blot analysis to detect
its level of acetylation (Fig. 1B). Co-transfection of active PCAF resulted in a significant acetylation of IRF7 that was not
observed when the HAT mutant form of PCAF was co-transfected. A darker
exposure of the gel showed that IRF7 was also basally acetylated in the
absence of transfected HAT proteins, although this acetylation was much
weaker (data not shown). As previously described, we observed a strong
auto-acetylation of PCAF (25). Similarly, GCN5, but not the GCN5 HAT
mutant, was able to acetylate IRF7 though to a much lesser extent than
PCAF. In contrast, p300 did not cause IRF7 acetylation (data not
shown). All three HAT proteins were active in that they were able to
acetylate endogenous substrates in vivo in transfected cells
(data not shown). Furthermore, over-expression of histone deacetylase 1 along with IRF7 and PCAF led to a significant decrease of the amount of
acetylated IRF7. Taken together, these results show that IRF7 is
subjected to reversible acetylation in vivo.
Lysine 92 Is the Unique Target for Acetylation by PCAF--
To map
the acetylation site(s), we co-transfected a series of deletion mutants
of IRF7 along with PCAF in 293T cells. As shown in Fig.
2A (right panel),
all the deletion mutants tested except Lysine 92 Is a Residue Critical for DNA Binding--
To
characterize the role of lysine 92 in IRF7 function, we tested the
ability of the K92R mutant to transactivate a typical IFN
Because DNA binding ability of WT-IRF7 is dramatically increased upon
virus-induced phosphorylation, it was important to ascertain whether
the K92R mutant was phosphorylated in virus-infected cells. The
presence of phosphorylated K92R mutant was monitored by the detection
of a slower migrating band after immunoblotting of virus-infected cell
extracts as observed for WT-IRF7. Fig. 3C shows that K92R was phosphorylated in virus-infected cells. The slight diminution in
phosphorylation compared with WTIRF7 is unlikely to account for the
major difference observed in DNA binding.
Acetylation Inhibits IRF7 DNA Binding and Activity--
The
abolition of DNA binding of the K92R mutant suggested that this lysine
might play a crucial role for DNA binding independently of its
acetylation status. To circumvent this problem, we sought to design an
IRF7 mutant that could not be acetylated but retained DNA binding
ability. In the course of understanding the structural determinants
driving acetylation by PCAF, the acetylation status of the closely
functionally and structurally related protein IRF3 was determined.
Despite the close identity between the two proteins, no acetylation of
IRF3 was detected in the presence of PCAF (see Fig.
4B, right panel,
lane 6). Taking advantage of this observation, we designed a
mutant where the amino acids surrounding the lysine acetylation target
were changed into those of IRF3 (G91T/T93R) (Fig.
4A). First, we verified that G91T/T93R had lost its ability to be acetylated by PCAF, as intended. GTTR showed an undetectable level of acetylation, comparable with IRF3 or IRF7 deletion mutant
To directly assess whether acetylation had an inhibitory effect on DNA
binding, purified GST-IRF7 was acetylated in vitro by PCAF
prior to incubation with biotinylated ISRE. ISRE-bound IRF7 was then
purified and detected by immunoblotting. As shown in Fig.
5A, acetylated IRF7 displayed
decreased DNA affinity when compared with non-acetylated IRF7. Greater
than 3-fold more IRF7 was recovered in the DNA-bound fraction in the
absence of acetylation (compare the Phosphorylation is considered the major posttranslational
modification responsible for activating signal transduction pathways. However, acetylation has been recently shown to be a widespread mechanism involved in regulating transcription factor activity. Here we
show that IRF7, a transducer of a virus-mediated signaling pathway, is
acetylated on lysine 92 within the DNA-binding domain by the
acetyltransferase PCAF. Moreover, acetylation of lysine 92 impaired DNA
binding ability and thus decreased transcriptional activity.
Our work is the first report of mapping an acetylation target residue
for a protein of the IRF family. As mentioned above, IRF1 and 2 have
been reported to be acetylated by p300 and PCAF within the DBD, but no
alteration of DNA binding activity was observed (24). Moreover, the
target residue(s) of acetylation were not mapped and therefore the
correspondence between the acetylation of IRF1, IRF2, and IRF7 cannot
be established. Recently, Suhara et al. (26) provided
evidence that p300 had a direct contribution to the binding of IRF3 to
DNA and that p300 was capable of acetylating IRF3 in vitro
but only when IRF3 was present as a dimer in the holocomplex. The
authors also suggested that acetylation of IRF3 was fundamental for
activation of the holocomplex because a p300 HAT mutant failed to
confer DNA binding activity. It is worth noting that acetylation by HAT
enzymes seems to be very specific because p300 acetylates IRF3 but is
not able to acetylate IRF7 and that PCAF shows an inverse specificity.
Furthermore, these two acetylation events, which most likely take place
on different sites, have opposite effects on the DNA binding ability of
IRF3 and IRF7.
It is interesting to point out that, whereas an increase in activity
has been observed upon acetylation of most transcription factors, some
factors like HMGI(Y), YY1, and CDP/cut show decreased DNA binding when
acetylated within their DNA-binding domain (27-29). The effect of
acetylation on DNA binding appears to correlate with the functional
domain where it takes place. Although increased DNA binding generally
results from acetylation in a domain nearby the DNA-binding domain
(E2F, EKLF, and p53), acetylation of lysine residues within the
DNA-binding domain has an inhibitory effect on DNA binding. As reported
for other DNA-binding proteins, many of the residues contacting the
negatively charged DNA backbone are positively charged lysine and
arginine residues. According to the crystal structure of the IRF1
DNA-binding domain bound to a DNA element from the interferon- Though the mechanism driving IRF7 acetylation remains to be
investigated, one can hypothesize that this phenomenon could be part of
an auto-regulatory loop. Indeed, as an initial response to viral
infection, cells produce a spectrum of early inflammatory cytokines,
including interferon, that can both activate immune cells and directly
inhibit viral replication. Host response to viral infection is potent
and can be deleterious to the cell; thus it is essential for cell
survival that this response be regulated in a precise spatial and
temporal manner. It has been shown that, in the context of the
interferon It is also notable that acetylation of IRF7 occurs in a region that
distinguishes its DNA binding from that of IRF3. Although IRF3 displays
relatively strong DNA binding, it has a weak transactivation domain
that appears to be completely dependent on p300 for induction of gene
expression. In contrast, IRF7 binds weakly to DNA due to a rapid off
rate, and this binding can be further reduced by acetylation of lysine
92. However, the potent transactivation domain of IRF7 that functions
independently from known co-activator HAT proteins produces robust
induction of IFN
genes and the onset of a potent
antiviral state. After induction of IRF7 by autocrine interferon,
latent IRF7 is activated by virus-induced phosphorylation on serine
residues within the C-terminal regulatory domain. Although it is
likely that IRF7 is subjected to a cascade of events responsible for regulating its biological activity, to date no mechanism other than
phosphorylation has been reported to modulate IRF7 activity. Here, we
report that IRF7 is acetylated in vivo by the histone acetyltransferases p300/CBP-associated factor (PCAF) and GCN5. The single lysine residue target for acetylation, lysine 92, is located
in the DNA-binding domain and is conserved throughout the entire IRF
family. Mutation of lysine 92 resulted in complete abolition of DNA
binding ability. However, a mutant that cannot be acetylated by PCAF
due to a change in the surrounding amino acid context of lysine 92 showed increased DNA binding and activity compared with wild type
IRF7. Conversely, we showed that acetylated IRF7 displayed
impaired DNA binding capability and that over-expression of PCAF led to
decreased IRF7 activity. Together, our results strongly suggest that
acetylation of lysine 92 negatively modulates IRF7 DNA binding.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and
4 (5). In contrast, IRF7 is
required for the induction of additional members of the IFN
multi-gene family (5, 11, 12). Although there are several structural
differences between IRF3 and IRF7 that could account for this
difference, the major determinant appears to be DNA binding
specificity. IRF3 binds with high affinity to relatively perfect GAA
repeat motifs found within the positive regulatory domain I of the
IFN
promoter and the IFN
4 promoter; in contrast, IRF7 displays a
more relaxed DNA binding specificity allowing it to bind variant
sequences found in promoters of the other IFN
genes (13). However,
the structural basis for differential DNA binding has not been elucidated.
amino group of certain lysine side chains. Transcription factors
that have been shown to be acetylated by different HAT proteins include p53, MyoD, HNF4, E2F1, and c-Myb. These acetylation events have been
shown to directly affect protein function. The consequence of
acetylation on protein function is highly variable from one protein to
another and depends on where within the protein the acetylation takes
place. For p53 and E2F1, for example, acetylation regulates DNA binding
(16, 17). Besides affecting DNA binding, acetylation has also been
reported to modulate protein-protein interactions. For example, the
association of nuclear receptors with their co-activator ACTR is
inhibited by acetylation (18). Protein stability is the third
characteristic to be altered by acetylation. Increased stability has
been correlated with acetylated E2F1 and
-tubulin (17, 19).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1-4 have been described
elsewhere (10). GST-IRF7DBD was generated by cloning the first 256 amino acids of IRF7 into the pGEX-2T vector using the BamHI
and EcoRI sites.
-galactosidase activity of a
co-transfected CMV-lacZ plasmid measured on a luminescent substrate.
Each construct was tested in duplicate in at least three independent
experiments. Results shown are from a single experiment representative
of results obtained.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (24K):
[in a new window]
Fig. 1.
In vivo acetylation of IRF7 by
PCAF and GCN5. A, 293T cells were transfected with
FLAG-tagged IRF7 and, after 16 h, were mock-infected or infected
with NDV for 7 h, as indicated. Nuclear extracts were
immunoprecipitated with anti-FLAG antibodies and analyzed by Western
blotting with anti-acetyl lysine antibodies. In the lower
panel the same membrane re-blotted with anti-IRF7 antibodies is
shown. B, 293T cells were transfected with FLAG-tagged IRF7
along with different expression constructs coding for histone
acetyltransferases (FLAG-tagged PCAF and FLAG-tagged GCN5) or their
corresponding inactive forms (HAT mutants) and histone deacetylase 1, as indicated. Whole cell extracts were immunoprecipitated with the
anti-FLAG antibody M2 and analyzed by Western blotting with
anti-acetylated lysine antibodies (upper panel). As a
loading control, 10% of the extracts used for immunoprecipitation were
subjected to direct immunoblotting using anti-FLAG antibodies
(lower panel). Respective sizes of PCAF, GCN5, and IRF7 are
indicated on the right.
2, which is missing the
DNA-binding domain, could still be acetylated by PCAF. Interestingly,
the mutant
1, missing only part of the DNA-binding domain, was
strongly acetylated. As mentioned above, acetylation occurs only on
lysine residues, and only two lysine residues were found in the
sequence of
1 that is missing in
2, at positions 43 and 92. Each
lysine residue was individually mutated to arginine and the point
mutants were tested for their ability to become acetylated by
over-expressed PCAF. As shown in Fig. 2A (right
panel), the mutant K92R lost its ability to be acetylated, whereas
K43R was acetylated as strongly as WTIRF7. Although we cannot exclude
the possibility that lysine 92 substitution to arginine alters
the recognition of IRF7 by PCAF, this result strongly suggests that
IRF7 is acetylated by PCAF on residue 92. As expected, the double
mutant K43R/K92R was also unable to be acetylated. Interestingly,
lysine residue 92 is conserved throughout the IRF family, suggesting
that it plays a fundamental role in transcription factor function (Fig.
2B).

View larger version (37K):
[in a new window]
Fig. 2.
Acetylation maps to lysine 92 in the
DNA-binding domain. A, 293T cells were transfected with
different FLAG-tagged deletion and point mutants (Lys to Arg) of
IRF7 along with FLAG-tagged PCAF as indicated (see schematic
representation of IRF7 deletion mutants on the left part of
the figure). Whole cell extracts were immunoprecipitated with the
anti-FLAG antibody M2 and analyzed by Western blotting with
anti-acetylated lysine antibodies (upper panel). As a
loading control, 10% of the extracts used for immunoprecipitation were
monitored by Western blotting using anti-FLAG antibodies (lower
panel). Respective sizes of PCAF, GCN5, and IRF7 are indicated on
the right. B, sequence comparison of the
surrounding sequence of lysine 92 with the sequence of the other murine
members of the family. The conserved lysine (corresponding to lysine 92 in IRF7) is highlighted in bold.
gene
promoter in a reporter assay. As depicted in Fig.
3A, K92R was completely devoid
of activity on the IFN
6 promoter, whereas WT-IRF7 activated this
promoter over 1000-fold following viral infection. However, the absence
of activity could be due to impaired DNA binding rather than to the
inability of the mutant to be acetylated. Indeed, as described for many
other DNA-binding proteins, charged lysines are crucial for stabilizing
DNA-protein complexes. To test this hypothesis, we investigated the DNA
binding ability of the K92R mutant by electromobility shift assay on an ISRE probe. As shown in Fig. 3B, the K92R mutant was unable
to bind DNA (compare lanes 3 and 4 with
lanes 7 and 8).

View larger version (28K):
[in a new window]
Fig. 3.
IRF7 K92R is devoid of activity and does not
bind DNA. A, COS cells were transfected with WT-IRF7 and
IRF7K92R (as indicated) along with a luciferase reporter driven by the
IFN
6 promoter. At 24 h after infection, cells were
mock-infected (black bars) or infected with NDV (gray
bars) for 12 h. Mean values from a representative experiment
are expressed as fold induction relative to cells transfected with an
empty vector after normalization to co-transfected
-galactosidase.
B, EMSA was performed on nuclear extracts derived from 293T
cells transfected with an empty vector or WT-IRF7 or IRF7K92R mutant
and PCAF that had been mock-infected or infected with NDV for 7 h,
as indicated. Extracts were incubated with an ISRE probe from the ISG15
gene. C, IRF7K92R is phosphorylated following infection by
NDV. 293T cells were transfected with WT-IRF7 or IRF7K92R. Nuclear
extracts were harvested after 7 h of mock or NDV infection and
analyzed for electrophoretic mobility by Western blotting using
anti-FLAG antibodies.
2
(Fig. 4B, compare lane 2 with lanes 4 and 6). This observation proved that the sequence context of
the target lysine is a determinant for its acetylation by PCAF. Second,
we tested whether this mutant retained DNA binding ability. GTTR was
still able to bind DNA, although it exhibited an altered pattern in
electromobility shift assay on an ISRE probe compared with WT-IRF7
(Fig. 4C). In a reporter assay using the IFN
6 promoter,
the IRF7GTTR mutant was over 30-fold more active than WT-IRF7 in
control cells and over 5-fold more active after viral infection (Fig.
4D). Thus, this double point mutant of IRF7, which cannot be
acetylated, displayed enhanced transcriptional activity. These results
strongly suggested that acetylation of lysine 92 imposes an inhibitory
effect on IRF7 activity. To confirm that this effect was due to
acetylation, it was important to verify that over-expression of PCAF
had no effect on IRF7GTTR DNA binding. As shown above (Fig.
3B, lanes 5 and 6), over-expression of
PCAF led to decreased DNA binding activity, whereas over-expression of
the PCAF HAT mutant had no effect on IRF7 DNA binding (Fig.
4E, left panel). In contrast, the IRF7GTTR mutant
was not affected by PCAF over-expression, strongly suggesting that the
inhibition of IRF7 DNA binding by PCAF was due to acetylation of lysine
92 (Fig. 4E, right panel). However, the slight
difference in DNA binding affinity between WT-IRF7 and IRF7GTTR was
unlikely to account for the substantial difference observed in the
transactivation activity assay. To explore possible reasons for the
increased transactivation ability of IRF7GTTR, the stability of the
IRF7GTTR and WT-IRF7 protein-DNA complexes were compared. The
dissociation rate of each complex was measured by challenging the
preformed complexes with a 500-fold molar excess of unlabelled ISRE
oligonucleotide. Half-lives of the complexes were calculated by
removing aliquots at serial time points and loading them onto a running
non-denaturing polyacrylamide gel. Dissociation of WT-IRF7 from
DNA was very rapid (<1 min), whereas the IRF7GTTR-ISRE interaction was
strikingly more stable, with a half-life of around 60 min (Fig.
4F). This indicates that the non-acetylatable IRF7GTTR
mutant has a substantially higher affinity for the ISRE, suggesting
that acetylation strongly impairs IRF7 affinity for its cognate DNA.
Interestingly, IRF3 complexes also showed a very high affinity for the
ISRE element, consistent with the finding that IRF3 is not acetylated
by PCAF (data not shown).

View larger version (51K):
[in a new window]
Fig. 4.
IRF7GTTR mutant exhibits increased DNA
binding and activity. A, sequence of the IRF7GTTR mutant is
shown and compared with murine IRF3 and IRF7. B, 293T cells
were transfected with FLAG-tagged WT-IRF7, IRF7GTTR, IRF7
2, and IRF3
along with FLAG-tagged PCAF, as indicated. Whole cell extracts were
immunoprecipitated with the anti-FLAG antibody M2 and analyzed by
Western blotting with anti-acetylated lysine antibodies (upper
panel). In the lower panel the same membrane blotted
with polyclonal anti-FLAG antibodies is shown. The respective sizes of
PCAF, IRF7, and IRF3 are indicated on the right. * indicates
some nonspecific bands (the apparent molecular weights of IRF7
2 and
IRF3 are smaller as shown in the lower panel). C,
EMSA was performed on nuclear extracts derived from 293T cells
transfected with an empty vector or WT-IRF7 or IRF7GTTR mutant that had
been mock- or NDV-infected for 7 h, as indicated. Extracts were
incubated with an ISRE probe from the ISG15 gene. D, COS
cells were transfected with WT-IRF7 and IRF7GTTR (as indicated) along
with a luciferase reporter driven by the IFN
6 promoter. At 24 h
after infection, cells were mock- (black bars) or
NDV-infected (gray bars) for 12 h. Mean values from a
representative experiment are expressed as fold induction relative to
cells transfected with an empty vector after normalization to
co-transfected
-galactosidase. E, EMSA was performed on
nuclear extracts derived from 293T cells transfected with an empty
vector or WT-IRF7 or IRF7GTTR mutant, along with PCAF when indicated,
that had been mock- or NDV-infected for 7 h, as indicated.
Extracts were incubated with an ISRE probe from the ISG15 gene.
F, protein-DNA complexes between IRF7WT or IRF7GTTR and a
labeled ISRE probe were formed using standard EMSA conditions. The
stability of these complexes was determined by measuring the amount of
residual labeled DNA bound to the proteins at indicated times (in min)
following addition of unlabeled ISRE nucleotide. Samples were loaded at
differing times throughout the experiment and were therefore
electrophoresed for different lengths of time, resulting in somewhat
different mobilities of the same complexes.
AcetylCoA panel to the
+AcetylCoA panel). This result is consistent with the
finding that over-expression of PCAF led to reduced DNA binding in an
electromobility shift assay, as shown in Fig. 3B (compare
lanes 5 and 6 to lanes 3 and
4). To test whether acetylation-dependent
inhibition of DNA binding impairs IRF7 activity, we co-transfected
increasing amounts of PCAF along with IRF7 in a reporter assay. We
observed a dose-dependent inhibition of IRF7-mediated activation of the IFN
6 promoter in infected cells (Fig.
5B). The 2-3-fold inhibition observed in this assay
correlates with the fold inhibition detected in the DNA affinity assay.
Taken together, our results strongly suggest that acetylation of IRF7 by PCAF is a reversible mechanism that modulates IRF7 DNA binding and
activity and targets a region that distinguishes IRF7 from its relative
IRF3.

View larger version (21K):
[in a new window]
Fig. 5.
Acetylation is detrimental to IRF7 DNA
binding and activity. A, purified GST-IRF7 DBD was
acetylated in vitro by PCAF in the presence or absence of
acetylCoA, as indicated, prior to incubation of the indicated amounts
of GST-IRF7 with biotinylated ISRE derived from the ISG15 gene. Bound
IRF7 was purified using streptavidin beads and detected by
immunobloting using anti-IRF7 antibodies. B, COS cells were
co-transfected with WT-IRF7 (100 ng) and increasing amounts of PCAF (0, 1000, and 2000 ng) along with a luciferase reporter driven by the
IFN
6 promoter. At 24 h after infection, cells were infected
with NDV for 12 h, and extracts were assayed for luciferase
activity. Mean values from a representative experiment are expressed as
fold induction relative to cells transfected with an empty vector after
normalization to co-transfected
-galactosidase.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
promoter, lysine 78 (corresponding to lysine 92 in IRF7) is responsible
for stabilizing the protein-DNA complex through hydrogen bonds (30).
The decreased DNA binding ability of IRF7 upon acetylation can be
likely explained by the neutralization of the positive charge of lysine
92 that is responsible for tightening the bonds between the
transcriptional complex and promoter.
enhanceosome, acetylation of HMGI(Y) on lysine 65 by CBP
leads to destabilization and disassembly of the transcriptional complex
(27). Our results favor the hypothesis that acetylation of IRF7 may
play a similar role in disrupting the transcriptional complex bound to
interferon
promoters and turning off type I interferon gene
induction. Alternatively, basal acetylation of IRF7 may be a regulatory
step that prevents non-activated IRF7 from binding DNA with high
affinity in the absence of the proper stimulus that will lead to its
deacetylation. The kinetics and nature of the different stimuli leading
to full activation of IRF7 and disruption of the active complex are not
fully clarified and need further characterization. Thus, acetylation is
likely to be a common mechanism for type I interferon gene repression.
genes following viral infection.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Y. Nakatani, R. Schiltz, S. Roth, M. Rosenfeld, and E. Verdin for the gift of plasmids. We thank Gregory David for helpful advice and critical reading of the manuscript. We thank Helene Collandre for helpful discussions.
| |
FOOTNOTES |
|---|
* This work was supported in part by grants from the Association sur la Recherche contre le Cancer (ARC) (to I. M.), by Grant R01 A146503 from the National Institute of Health, and by Grant 9951033T from the American Heart Association.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Recipient of a fellowship from ARC.
** To whom correspondence should be addressed: Dept. of Pathology, New York University School of Medicine, 550 First Ave., MSB 556, New York, NY 10016. Tel.: 212-263-8705; Fax: 212-263-8211; E-mail: isabellemarie@hotmail.com.
Published, JBC Papers in Press, October 8, 2002, DOI 10.1074/jbc.M207484200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: IRF, interferon regulatory factor; IFN, interferon; HAT, histone acetyltransferase; DBD, DNA-binding domain; CBP, CREB-binding protein; PCAF, p300/CBP-associated factor; HMG, high mobility group; acetylCoA, acetylcoenzyme A; ISRE, interferon-stimulated response element; ISG, interferon-stimulated gene; EMSA, electromobility shift assay; WT, wild type; NDV, Newcastle disease virus; GST, glutathione S-transferase; CREB, cAMP-response element-binding protein.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Nguyen, H., Hiscott, J., and Pitha, P. M. (1997) Cytokine Growth Factor Rev. 8, 293-312[CrossRef][Medline] [Order article via Infotrieve] |
| 2. |
Nehyba, J.,
Hrdlickova, R.,
Burnside, J.,
and Bose, H. R., Jr.
(2002)
Mol. Cell. Biol.
22,
3942-3957 |
| 3. | Barnes, B., Lubyova, B., and Pitha, P. M. (2002) J. Interferon Cytokine Res. 22, 59-71[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Veals, S. A.,
Schindler, C.,
Leonard, D., Fu, X. Y.,
Aebersold, R.,
Darnell, J. E., Jr.,
and Levy, D. E.
(1992)
Mol. Cell. Biol.
12,
3315-3324 |
| 5. | Marie, I., Durbin, J. E., and Levy, D. E. (1998) EMBO J. 17, 6660-6669[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Wathelet, M. G., Lin, C. H., Parekh, B. S., Ronco, L. V., Howley, P. M., and Maniatis, T. (1998) Mol. Cell 1, 507-518[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Yoneyama, M., Suhara, W., Fukuhara, Y., Fukuda, M., Nishida, E., and Fujita, T. (1998) EMBO J. 17, 1087-1095[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Au, W. C.,
Moore, P. A.,
LaFleur, D. W.,
Tombal, B.,
and Pitha, P. M.
(1998)
J. Biol. Chem.
273,
29210-29217 |
| 9. |
Lin, R.,
Heylbroeck, C.,
Pitha, P. M.,
and Hiscott, J.
(1998)
Mol. Cell. Biol.
18,
2986-2996 |
| 10. |
Marie, I.,
Smith, E.,
Prakash, A.,
and Levy, D. E.
(2000)
Mol. Cell. Biol.
20,
8803-8814 |
| 11. | Sato, M., Hata, N., Asagiri, M., Nakaya, T., Taniguchi, T., and Tanaka, N. (1998) FEBS Lett. 441, 106-110[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Sato, M., Suemori, H., Hata, N., Asagiri, M., Ogasawara, K., Nakao, K., Nakaya, T., Katsuki, M., Noguchi, S., Tanaka, N., and Taniguchi, T. (2000) Immunity 13, 539-548[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Lin, R.,
Mamane, Y.,
and Hiscott, J.
(2000)
J. Biol. Chem.
275,
34320-34327 |
| 14. |
Sterner, D. E.,
and Berger, S. L.
(2000)
Microbiol. Mol. Biol. Rev.
64,
435-459 |
| 15. | Kouzarides, T. (1999) Curr. Opin. Genet. Dev. 9, 40-48[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Gu, W., and Roeder, R. G. (1997) Cell 90, 595-606[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Martinez-Balbas, M. A., Bauer, U. M., Nielsen, S. J., Brehm, A., and Kouzarides, T. (2000) EMBO J. 19, 662-671[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Chen, H., Lin, R. J., Xie, W., Wilpitz, D., and Evans, R. M. (1999) Cell 98, 675-686[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Takemura, R.,
Okabe, S.,
Umeyama, T.,
Kanai, Y.,
Cowan, N. J.,
and Hirokawa, N.
(1992)
J. Cell Sci.
103,
953-964 |
| 20. |
Silvennoinen, O.,
Schindler, C.,
Schlessinger, J.,
and Levy, D. E.
(1993)
Science
261,
1736-1739 |
| 21. | Levy, D. E. (1998) Methods 15, 167-174[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Kessler, D. S.,
Veals, S. A., Fu, X. Y.,
and Levy, D. E.
(1990)
Genes Dev.
4,
1753-1765 |
| 23. | Paulson, M., Press, C., Smith, E., Tanese, N., and Levy, D. E. (2002) Nat. Cell. Biol. 4, 140-147[CrossRef][Medline] [Order article via Infotrieve] |
| 24. |
Masumi, A.,
and Ozato, K.
(2001)
J. Biol. Chem.
276,
20973-20980 |
| 25. |
Herrera, J. E.,
Bergel, M.,
Yang, X. J.,
Nakatani, Y.,
and Bustin, M.
(1997)
J. Biol. Chem.
272,
27253-27258 |
| 26. |
Suhara, W.,
Yoneyama, M.,
Kitabayashi, I.,
and Fujita, T.
(2002)
J. Biol. Chem.
277,
22304-22313 |
| 27. | Munshi, N., Merika, M., Yie, J., Senger, K., Chen, G., and Thanos, D. (1998) Mol. Cell 2, 457-467[CrossRef][Medline] [Order article via Infotrieve] |
| 28. |
Yao, Y. L.,
Yang, W. M.,
and Seto, E.
(2001)
Mol. Cell. Biol.
21,
5979-5991 |
| 29. |
Li, S.,
Aufiero, B.,
Schiltz, R. L.,
and Walsh, M. J.
(2000)
Proc. Natl. Acad. Sci. U. S. A
97,
7166-7171 |
| 30. | Escalante, C. R., Yie, J., Thanos, D., and Aggarwal, A. K. (1998) Nature 391, 103-106[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
A. Sabo, M. Lusic, A. Cereseto, and M. Giacca Acetylation of Conserved Lysines in the Catalytic Core of Cyclin-Dependent Kinase 9 Inhibits Kinase Activity and Regulates Transcription Mol. Cell. Biol., April 1, 2008; 28(7): 2201 - 2212. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ozato, P. Tailor, and T. Kubota The Interferon Regulatory Factor Family in Host Defense: Mechanism of Action J. Biol. Chem., July 13, 2007; 282(28): 20065 - 20069. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Sariol, J. L. Munoz-Jordan, K. Abel, L. C. Rosado, P. Pantoja, L. Giavedoni, I. V. Rodriguez, L. J. White, M. Martinez, T. Arana, et al. Transcriptional Activation of Interferon-Stimulated Genes but Not of Cytokine Genes after Primary Infection of Rhesus Macaques with Dengue Virus Type 1 Clin. Vaccine Immunol., June 1, 2007; 14(6): 756 - 766. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-S. Chen, Y.-C. Wang, H.-C. Yang, P.-H. Huang, S. K. Kulp, C.-C. Yang, Y.-S. Lu, S. Matsuyama, C.-Y. Chen, and C.-S. Chen Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation Cancer Res., June 1, 2007; 67(11): 5318 - 5327. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Fanning, T. C. George, D. Feng, S. B. Feldman, N. J. Megjugorac, A. G. Izaguirre, and P. Fitzgerald-Bocarsly Receptor Cross-Linking on Human Plasmacytoid Dendritic Cells Leads to the Regulation of IFN-{alpha} Production J. Immunol., November 1, 2006; 177(9): 5829 - 5839. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-D. Chou, A. N. H. Khan, W. J. Magner, and T. B. Tomasi Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells Int. Immunol., November 1, 2005; 17(11): 1483 - 1494. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sakamoto, R. Potla, and A. C. Larner Histone Deacetylase Activity Is Required to Recruit RNA Polymerase II to the Promoters of Selected Interferon-stimulated Early Response Genes J. Biol. Chem., September 24, 2004; 279(39): 40362 - 40367. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lubyova, M. J. Kellum, A. J. Frisancho, and P. M. Pitha Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Stimulates the Transcriptional Activity of Cellular IRF-3 and IRF-7 J. Biol. Chem., February 27, 2004; 279(9): 7643 - 7654. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Buryskova, M. Pospisek, A. Grothey, T. Simmet, and L. Burysek Intracellular Interleukin-1{alpha} Functionally Interacts with Histone Acetyltransferase Complexes J. Biol. Chem., February 6, 2004; 279(6): 4017 - 4026. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Nusinzon and C. M. Horvath Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1 PNAS, December 9, 2003; 100(25): 14742 - 14747. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Masumi, Y. Yamakawa, H. Fukazawa, K. Ozato, and K. Komuro Interferon Regulatory Factor-2 Regulates Cell Growth through Its Acetylation J. Biol. Chem., July 3, 2003; 278(28): 25401 - 25407. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Barnes, A. E. Field, and P. M. Pitha-Rowe Virus-induced Heterodimer Formation between IRF-5 and IRF-7 Modulates Assembly of the IFNA Enhanceosome in Vivo and Transcriptional Activity of IFNA Genes J. Biol. Chem., May 2, 2003; 278(19): 16630 - 16641. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |